Mikhael, Joseph

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

Kumar, S. K., Lee, J. H., Lahuerta, J. J., Morgan, G., Richardson, P. G., Crowley, J., Haessler, J., Feather, J., Hoering, A., Moreau, P., et al. (2012) · Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 721

Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines

Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., et al. (2009) · Mayo Clinic Proceedings

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 628

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

Richardson, P. G., Siegel, D. S., Vij, R., Hofmeister, C. C., Baz, R., Jagannath, S., Chen, C., Lonial, S., Jakubowiak, A., Bahlis, N., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 381

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

Lacy, M. Q., Hayman, S. R., Gertz, M. A., Dispenzieri, A., Buadi, F., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2009) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 317

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease

Lacy, M. Q., Allred, J. B., Gertz, M. A., Hayman, S. R., Short, K. D., Buadi, F., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., et al. (2011) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 222

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma

Zhu, Y. X., Braggio, E., Shi, C.-X., Kortuem, K. M., Bruins, L. A., Schmidt, J. E., Chang, X.-B., Langlais, P., Luo, M., Jedlowski, P., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 213

Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)

Lacy, M. Q., Hayman, S. R., Gertz, M. A., Short, K. D., Dispenzieri, A., Kumar, S., Greipp, P. R., Lust, J. A., Russell, S. J., Dingli, D., et al. (2010) · Leukemia

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 197

Treatment options for triple-class refractory multiple myeloma.

Mikhael, J. (2020) · Clinical Lymphoma Myeloma and Leukemia

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 126

The clinical significance of cereblon expression in multiple myeloma

Schuster, S. R., Kortuem, K. M., Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Ahmann, G., Kumar, S., Rajkumar, S. V., et al. (2014) · Leukemia Research

Multiple Myeloma Research and TreatmentsProtein Degradation and Inhibitors

Cited by 113

A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma

Mikhael, J., Richter, J., Vij, R., Cole, C., Zonder, J., Kaufman, J. L., Bensinger, W., Dimopoulos, M., Lendvai, N., Hari, P., et al. (2020) · Leukemia

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 54

VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

Moreau, P., Dimopoulos, M. A. C., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Casca, F., Mace, S., et al. (2022) · Annals of Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18